Leonabio Inc (LONA)

$8.61 -0.02 (-0.23%)
Market Cap 81.07M
Revenue (ttm) 0.00
Net Income (ttm) -105.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 18,400
Avg Vol 41,334
Day's Range N/A - N/A
Shares Out 9.39M
Stochastic %K 1%
Beta 1.97
Analysts Strong Sell
Price Target $18.00

Company Profile

LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name...

Industry: Biotechnology
Sector: Healthcare
Phone: 425 620 8501
Address:
18706 North Creek Parkway, Suite 104, Bothell, United States
bluedetox
bluedetox Jun. 3 at 4:06 PM
$LONA if you short this you burnnn
0 · Reply
bluedetox
bluedetox Jun. 1 at 1:39 PM
$LONA
0 · Reply
SuperGreenToday
SuperGreenToday May. 27 at 4:55 PM
$LONA
0 · Reply
BullJack
BullJack May. 13 at 7:36 PM
$LONA perceptive advisors took a 20% stake and was granted a board seat. Premier biotech fund. $VERA i like a continued run up to FDA DATE $FBIO and DERM - following buymoremakemore’s DD here. The rosacea treatment seems to really be working. Tons of Reddit posts by public. Sales should only increase.
1 · Reply
Dr_Stoxx
Dr_Stoxx Apr. 9 at 8:38 PM
We only had 2 shorts pass our filters this week in the MOMENTUM LETTER, but they are doing really well in a strong upside market: $LONA and $FSLY I'll be sending out next week's Top 3 Momo SHORTS Sunday night. Join us!
1 · Reply
Anonymcq
Anonymcq Apr. 8 at 5:37 PM
$LONA why the drop here? I’m not seeing any news or SEC filings?
0 · Reply
Doozio
Doozio Apr. 4 at 6:52 PM
$LONA 🐒🍌🧠⏰♾️
0 · Reply
bb06
bb06 Apr. 2 at 10:52 PM
$LONA I see a buyout over the W/E...
0 · Reply
STACKD0E
STACKD0E Mar. 18 at 2:17 PM
$LONA
0 · Reply
Spicy_Trade
Spicy_Trade Mar. 18 at 2:15 PM
SpicyTrade LeonaBio, Inc. ( $LONA ) daily stock analysis https://youtu.be/s1knnYRMF5w?si=Ka0Y8K7hpC7D3CBE
0 · Reply
Latest News on LONA
LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit

Jun 4, 2026, 7:00 AM EDT - 16 hours ago

LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit

LeonaBio to Participate in Upcoming Medical and Industry Meetings in June

May 27, 2026, 7:00 AM EDT - 8 days ago

LeonaBio to Participate in Upcoming Medical and Industry Meetings in June

LeonaBio initiated with an Overweight at Piper Sandler

2026-05-27T08:55:08.000Z - 8 days ago

LeonaBio initiated with an Overweight at Piper Sandler

LeonaBio Proxy statement: Proxy filing

May 11, 2026, 8:00 AM EDT - 24 days ago

LeonaBio Proxy statement: Proxy filing

LeonaBio Proxy statement: Proxy filing

May 11, 2026, 8:00 AM EDT - 24 days ago

LeonaBio Proxy statement: Proxy filing

LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update

May 7, 2026, 4:05 PM EDT - 4 weeks ago

LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update

MRUS

LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B.

May 7, 2026, 9:20 AM EDT - 4 weeks ago

LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B.

LeonaBio Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

LeonaBio Quarterly report: Q1 2026

LeonaBio Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

LeonaBio Earnings release: Q1 2026

LeonaBio Transcript: Status update

Apr 29, 2026, 12:00 PM EDT - 5 weeks ago

LeonaBio Transcript: Status update

LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer

Apr 23, 2026, 4:05 PM EDT - 6 weeks ago

LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer

LeonaBio presented data on lasofoxifene research at AACR26

2026-04-21T12:33:02.000Z - 6 weeks ago

LeonaBio presented data on lasofoxifene research at AACR26

LeonaBio price target raised to $16 from $10 at Mizuho

2026-04-06T13:21:39.000Z - 2 months ago

LeonaBio price target raised to $16 from $10 at Mizuho

LeonaBio Registration statement: Registration filing

Mar 31, 2026, 8:00 AM EDT - 2 months ago

LeonaBio Registration statement: Registration filing

LeonaBio Registration statement: Registration filing

Mar 31, 2026, 8:00 AM EDT - 2 months ago

LeonaBio Registration statement: Registration filing

LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update

Mar 26, 2026, 5:10 PM EDT - 2 months ago

LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update

LeonaBio Annual report: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 2 months ago

LeonaBio Annual report: Q4 2025

LeonaBio Earnings release: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 2 months ago

LeonaBio Earnings release: Q4 2025

LeonaBio Transcript: EGM 2026

Mar 18, 2026, 11:00 AM EDT - 2 months ago

LeonaBio Transcript: EGM 2026

LeonaBio Proxy statement: Proxy Filing

Mar 10, 2026, 8:00 AM EDT - 3 months ago

LeonaBio Proxy statement: Proxy Filing

LeonaBio initiated with an Overweight at Cantor Fitzgerald

2026-02-26T13:48:30.000Z - 3 months ago

LeonaBio initiated with an Overweight at Cantor Fitzgerald

LeonaBio Proxy statement: Proxy Filing

Feb 23, 2026, 7:00 AM EST - 3 months ago

LeonaBio Proxy statement: Proxy Filing

LeonaBio upgraded to Outperform from Neutral at Mizuho

2026-02-18T21:46:53.000Z - 3 months ago

LeonaBio upgraded to Outperform from Neutral at Mizuho

LeonaBio Proxy statement: Proxy Filing

Feb 4, 2026, 7:00 AM EST - 4 months ago

LeonaBio Proxy statement: Proxy Filing

LeonaBio appoints Kubik as Chief Business Officer

2026-02-03T12:10:18.000Z - 4 months ago

LeonaBio appoints Kubik as Chief Business Officer

LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer

Feb 3, 2026, 7:00 AM EST - 4 months ago

LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer

LeonaBio files to sell 5.5M shares of common stock for holders

2026-01-20T21:50:31.000Z - 4 months ago

LeonaBio files to sell 5.5M shares of common stock for holders

LeonaBio Registration statement: Registration Filing

Jan 20, 2026, 7:00 AM EST - 4 months ago

LeonaBio Registration statement: Registration Filing

LeonaBio Registration statement: Registration Filing

Jan 20, 2026, 7:00 AM EST - 4 months ago

LeonaBio Registration statement: Registration Filing

Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment

Dec 18, 2025, 1:09 PM EST - 6 months ago

Athira Pharma recovers from Alzheimer's failure with breast cancer pivot and $90M investment

LeonaBio Transcript: Status Update

Dec 18, 2025, 8:30 AM EST - 6 months ago

LeonaBio Transcript: Status Update

LeonaBio Press release: Status Update

Dec 18, 2025, 8:30 AM EST - 6 months ago

LeonaBio Press release: Status Update

LeonaBio Slides: Status Update

Dec 18, 2025, 8:30 AM EST - 6 months ago

LeonaBio Slides: Status Update

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Dec 18, 2025, 7:02 AM EST - 6 months ago

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

LeonaBio Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

LeonaBio Earnings release: Q3 2025

LeonaBio Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

LeonaBio Quarterly report: Q3 2025

Athira Pharma Announces Reverse Stock Split

Sep 11, 2025, 9:00 AM EDT - 9 months ago

Athira Pharma Announces Reverse Stock Split

LeonaBio Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 10 months ago

LeonaBio Earnings release: Q2 2025

LeonaBio Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 10 months ago

LeonaBio Quarterly report: Q2 2025

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

May 13, 2025, 11:00 AM EDT - 1 year ago

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

May 9, 2025, 4:05 PM EDT - 1 year ago

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

LeonaBio Earnings release: Q1 2025

May 9, 2025, 4:00 PM EDT - 1 year ago

LeonaBio Earnings release: Q1 2025

LeonaBio Quarterly report: Q1 2025

May 9, 2025, 4:00 PM EDT - 1 year ago

LeonaBio Quarterly report: Q1 2025

LeonaBio Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

LeonaBio Proxy statement: Proxy Filing

LeonaBio Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

LeonaBio Proxy statement: Proxy Filing

LeonaBio Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

LeonaBio Proxy statement: Proxy Filing

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

Feb 27, 2025, 4:05 PM EST - 1 year ago

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

LeonaBio Annual report: Q4 2024

Feb 27, 2025, 4:00 PM EST - 1 year ago

LeonaBio Annual report: Q4 2024

LeonaBio Earnings release: Q4 2024

Feb 27, 2025, 4:00 PM EST - 1 year ago

LeonaBio Earnings release: Q4 2024

Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct

Jan 7, 2025, 5:15 PM EST - 1 year ago

Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Dec 6, 2024, 5:30 PM EST - 1 year ago

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Nov 7, 2024, 4:05 PM EST - 1 year ago

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

LeonaBio Earnings release: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

LeonaBio Earnings release: Q3 2024

LeonaBio Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

LeonaBio Quarterly report: Q3 2024

LeonaBio Registration statement: Registration Filing

Oct 21, 2024, 8:00 AM EDT - 1 year ago

LeonaBio Registration statement: Registration Filing

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring

Sep 17, 2024, 11:59 AM EDT - 1 year ago

Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Sep 17, 2024, 9:00 AM EDT - 1 year ago

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial

Sep 3, 2024, 4:13 PM EDT - 1 year ago

Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

Aug 1, 2024, 4:05 PM EDT - 2 years ago

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

LeonaBio Quarterly report: Q2 2024

Aug 1, 2024, 4:00 PM EDT - 2 years ago

LeonaBio Quarterly report: Q2 2024

LeonaBio Earnings release: Q2 2024

Aug 1, 2024, 4:00 PM EDT - 2 years ago

LeonaBio Earnings release: Q2 2024

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024

Jul 31, 2024, 8:05 AM EDT - 2 years ago

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024

LeonaBio Transcript: Status Update

Jun 18, 2024, 11:30 AM EDT - 2 years ago

LeonaBio Transcript: Status Update

LeonaBio Slides: Status Update

Jun 18, 2024, 11:30 AM EDT - 2 years ago

LeonaBio Slides: Status Update

LeonaBio Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 12, 2024, 2:00 PM EDT - 2 years ago

LeonaBio Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

Jun 12, 2024, 7:00 AM EDT - 2 years ago

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

LeonaBio Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 4:30 PM EDT - 2 years ago

LeonaBio Transcript: Jefferies 2024 Global Healthcare Conference

Athira Pharma to Participate in Upcoming June Conferences

May 29, 2024, 7:00 AM EDT - 2 years ago

Athira Pharma to Participate in Upcoming June Conferences

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

May 17, 2024, 5:00 PM EDT - 2 years ago

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

May 15, 2024, 4:05 PM EDT - 2 years ago

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

LeonaBio Quarterly report: Q1 2024

May 15, 2024, 4:00 PM EDT - 2 years ago

LeonaBio Quarterly report: Q1 2024

LeonaBio Earnings release: Q1 2024

May 15, 2024, 4:00 PM EDT - 2 years ago

LeonaBio Earnings release: Q1 2024

Athira Pharma to Participate in Upcoming May Conferences

May 2, 2024, 7:00 AM EDT - 2 years ago

Athira Pharma to Participate in Upcoming May Conferences

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

Apr 11, 2024, 7:00 AM EDT - 2 years ago

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease

LeonaBio Proxy statement: Proxy Filing

Apr 9, 2024, 8:00 AM EDT - 2 years ago

LeonaBio Proxy statement: Proxy Filing

LeonaBio Proxy statement: Proxy Filing

Apr 9, 2024, 8:00 AM EDT - 2 years ago

LeonaBio Proxy statement: Proxy Filing

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

LeonaBio Proxy statement: Proxy Filing

Mar 28, 2024, 8:00 AM EDT - 2 years ago

LeonaBio Proxy statement: Proxy Filing

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference

Mar 8, 2024, 7:00 AM EST - 2 years ago

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD™ 2024 International Conference

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Feb 22, 2024, 4:05 PM EST - 2 years ago

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

LeonaBio Annual report: Q4 2023

Feb 22, 2024, 7:00 AM EST - 2 years ago

LeonaBio Annual report: Q4 2023

LeonaBio Earnings release: Q4 2023

Feb 22, 2024, 7:00 AM EST - 2 years ago

LeonaBio Earnings release: Q4 2023

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Feb 8, 2024, 4:02 PM EST - 2 years ago

Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

Jan 8, 2024, 7:00 AM EST - 2 years ago

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

Jan 3, 2024, 7:00 AM EST - 2 years ago

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Dec 12, 2023, 7:00 AM EST - 2 years ago

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Nov 29, 2023, 7:00 AM EST - 2 years ago

Athira Pharma to Participate in Sidoti December Small Cap Investor Conference

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

Nov 15, 2023, 8:15 AM EST - 2 years ago

Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease

LeonaBio Quarterly report: Q3 2023

Nov 9, 2023, 3:00 AM EST - 2 years ago

LeonaBio Quarterly report: Q3 2023

LeonaBio Earnings release: Q3 2023

Nov 9, 2023, 3:00 AM EST - 2 years ago

LeonaBio Earnings release: Q3 2023

Athira Pharma to Participate in Jefferies London Healthcare Conference

Nov 8, 2023, 7:00 AM EST - 2 years ago

Athira Pharma to Participate in Jefferies London Healthcare Conference

Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Oct 5, 2023, 4:30 PM EDT - 2 years ago

Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2023, 7:00 AM EDT - 2 years ago

Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates

Aug 10, 2023, 4:05 PM EDT - 3 years ago

Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates

LeonaBio Quarterly report: Q2 2023

Aug 10, 2023, 3:00 AM EDT - 3 years ago

LeonaBio Quarterly report: Q2 2023

LeonaBio Earnings release: Q2 2023

Aug 10, 2023, 3:00 AM EDT - 3 years ago

LeonaBio Earnings release: Q2 2023

Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer's Disease

Jul 17, 2023, 7:00 AM EDT - 3 years ago

Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer's Disease

Athira Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2023

Jul 6, 2023, 7:00 AM EDT - 3 years ago

Athira Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2023

Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

May 22, 2023, 7:00 AM EDT - 3 years ago

Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer

LeonaBio Quarterly report: Q1 2023

May 11, 2023, 3:00 AM EDT - 3 years ago

LeonaBio Quarterly report: Q1 2023

LeonaBio Earnings release: Q1 2023

May 11, 2023, 3:00 AM EDT - 3 years ago

LeonaBio Earnings release: Q1 2023

Athira Pharma to Participate in Upcoming May Investor Conferences

May 8, 2023, 7:00 AM EDT - 3 years ago

Athira Pharma to Participate in Upcoming May Investor Conferences

Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting

Apr 25, 2023, 4:01 PM EDT - 3 years ago

Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting

Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting

Apr 11, 2023, 7:00 AM EDT - 3 years ago

Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting

LeonaBio Proxy statement: Proxy Filing

Apr 5, 2023, 8:00 AM EDT - 3 years ago

LeonaBio Proxy statement: Proxy Filing

LeonaBio Proxy statement: Proxy Filing

Apr 5, 2023, 8:00 AM EDT - 3 years ago

LeonaBio Proxy statement: Proxy Filing

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer's and Parkinson's Diseases at AD/PD™ 2023 International Conference

Mar 28, 2023, 1:00 AM EDT - 3 years ago

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer's and Parkinson's Diseases at AD/PD™ 2023 International Conference

Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates

Mar 23, 2023, 4:05 PM EDT - 3 years ago

Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates

bluedetox
bluedetox Jun. 3 at 4:06 PM
$LONA if you short this you burnnn
0 · Reply
bluedetox
bluedetox Jun. 1 at 1:39 PM
$LONA
0 · Reply
SuperGreenToday
SuperGreenToday May. 27 at 4:55 PM
$LONA
0 · Reply
BullJack
BullJack May. 13 at 7:36 PM
$LONA perceptive advisors took a 20% stake and was granted a board seat. Premier biotech fund. $VERA i like a continued run up to FDA DATE $FBIO and DERM - following buymoremakemore’s DD here. The rosacea treatment seems to really be working. Tons of Reddit posts by public. Sales should only increase.
1 · Reply
Dr_Stoxx
Dr_Stoxx Apr. 9 at 8:38 PM
We only had 2 shorts pass our filters this week in the MOMENTUM LETTER, but they are doing really well in a strong upside market: $LONA and $FSLY I'll be sending out next week's Top 3 Momo SHORTS Sunday night. Join us!
1 · Reply
Anonymcq
Anonymcq Apr. 8 at 5:37 PM
$LONA why the drop here? I’m not seeing any news or SEC filings?
0 · Reply
Doozio
Doozio Apr. 4 at 6:52 PM
$LONA 🐒🍌🧠⏰♾️
0 · Reply
bb06
bb06 Apr. 2 at 10:52 PM
$LONA I see a buyout over the W/E...
0 · Reply
STACKD0E
STACKD0E Mar. 18 at 2:17 PM
$LONA
0 · Reply
Spicy_Trade
Spicy_Trade Mar. 18 at 2:15 PM
SpicyTrade LeonaBio, Inc. ( $LONA ) daily stock analysis https://youtu.be/s1knnYRMF5w?si=Ka0Y8K7hpC7D3CBE
0 · Reply
topstockalerts
topstockalerts Mar. 17 at 8:31 PM
Top Gainers PT2 $INLF $KRKR $LONA $LMNX $ISPR
0 · Reply
Jteee
Jteee Mar. 17 at 7:52 PM
$LONA flying high
0 · Reply
Tradebub
Tradebub Mar. 17 at 7:49 PM
$LONA
0 · Reply
SebNo1234
SebNo1234 Mar. 17 at 7:40 PM
$LONA looks wonderful😎🚀🍀👍🚀🚀
0 · Reply
topstockalerts
topstockalerts Mar. 16 at 4:16 PM
$LONA Starting to wake up as volume increases. Buyers are getting more aggressive at these levels. Worth keeping this on radar.
0 · Reply
SebNo1234
SebNo1234 Mar. 16 at 3:32 PM
$LONA Analysts' price target is $10... so it can still gain a few percent.😎🚀🚀🍀🍀
0 · Reply
PPalisades
PPalisades Mar. 16 at 3:13 PM
$LONA Whats going up here?;)
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 11 at 12:05 AM
$LONA Current Stock Price: $6.58
0 · Reply
SebNo1234
SebNo1234 Mar. 10 at 5:00 PM
$LONA
0 · Reply